>
Researchers discover revolutionary material that could shatter the limits of traditional solar panel
Scientists Tested 8 Famous Cities. Only 1 Met The Standard For Tree Cover
How Long You Can Balance on 1 Leg Reveals Neuromuscular Aging
Leukemia: Symptoms, Causes, Treatments, and Natural Approaches
Forget Houston. This Space Balloon Will Launch You to the Edge of the Cosmos From a Floating...
SpaceX and NASA show off how Starship will help astronauts land on the moon (images)
How aged cells in one organ can cause a cascade of organ failure
World's most advanced hypergravity facility is now open for business
New Low-Carbon Concrete Outperforms Today's Highway Material While Cutting Costs in Minnesota
Spinning fusion fuel for efficiency and Burn Tritium Ten Times More Efficiently
Rocket plane makes first civil supersonic flight since Concorde
Muscle-powered mechanism desalinates up to 8 liters of seawater per hour
Student-built rocket breaks space altitude record as it hits hypersonic speeds
Researchers discover revolutionary material that could shatter limits of traditional solar panels
Total color blindness, or achromatopsia, is generally an inherited disease caused by mutations in one of six different genes, with the majority of cases involving variants in either the CNGA3 or CNGB3 genes. The new gene therapy being trialed focuses on correcting a defect in the CNGA3 gene.
The treatment is somewhat similar to one of the first FDA-approved gene therapies, for vision loss, called Luxturna. These treatments attach a healthy functioning gene to a genetically modified harmless virus. The treatment is injected into a patient's eye and hopefully the correctly functioning gene begins producing whatever protein was previously missing, helping cure the condition caused by the defective gene.